Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

Séverine Vermeire, William J. Sandborn, Silvio Danese, +17

The Lancet

InflammationAutoimmune DiseaseMucosal ImmunologyImmunologyGastroenterology +7

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study

William J. Sandborn, Scott D. Lee, Dino Tarabar, +17

Gut

Phase 2: a dose-escalation study of OncoGel (ReGel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to external-beam radiation in patients with inoperable esophageal cancer

G.A. DuVall, Dino Tarabar, Richard Seidel, +2

Anti-Cancer Drugs

Dose-escalation StudyInjection SiteRadiation MedicineEsophageal CancerRadiation Therapy +12

Onercept for Moderate-to-Severe Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial

Paul Rutgeerts, William J. Sandborn, Richard N. Fedorak, +8

Clinical Gastroenterology and Hepatology

Anti-inflammatoryFunctional Gastrointestinal DisorderPharmacologyGastroenterologyClinical Trials +3

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Silvio Danese, Remo Panaccione, Brian G. Feagan, +137

˜The œLancet. Gastroenterology & hepatology

UrologyMoxibustionGastroenterologyDouble-blind Galaxi-1 TrialMaintenance Results +4

Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year

Peter G. Gibson, Brian G. Feagan, William J. Sandborn, +8

Clinical and Translational Gastroenterology

Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension

Walter Reinisch, Peter G. Gibson, William J. Sandborn, +9

Journal of Crohn s and Colitis

Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II

Walter Reinisch, William J. Sandborn, Silvio Danese, +15

Journal of Crohn s and Colitis

A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab

Dino Tarabar, Katia El Jurdi, Cindy Traboulsi, +10

Inflammatory Bowel Diseases

901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT Study

Walter Reinisch, William J. Sandborn, Silvio Danese, +16

Gastroenterology

InflammationTurandot StudyImmunologyGastroenterologySevere Ulcerative Colitis +4